

## Role of the Scavenger Receptor MARCO in Alveolar Macrophage Binding of Unopsonized Environmental Particles

By Aiyappa Palecanda,\* Joseph Paulauskis,\* Eiman Al-Mutairi,\* Amy Imrich,\* Guozhong Qin,\* Hiroshi Suzuki,<sup>§</sup> Tatsuhiko Kodama,<sup>§</sup> Karl Tryggvason,<sup>||</sup> Henry Koziel,<sup>¶</sup> and Lester Kobzik<sup>‡</sup>

From the \*Physiology Program, Harvard School of Public Health, Boston, Massachusetts 02115; the

<sup>‡</sup>Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts 02115; the

<sup>§</sup>Department of Molecular Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo 153, Japan; the <sup>||</sup>Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden; and the <sup>¶</sup>Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215

### Summary

Alveolar macrophages (AMs) avidly bind and ingest unopsonized environmental particles and bacteria through scavenger-type receptors (SRs). AMs from mice with a genetic deletion of the major macrophage SR (types AI and AII; SR<sup>-/-</sup>) showed no decrease in particle binding compared with SR<sup>+/+</sup> mice, suggesting that other SRs are involved. To identify these receptors, we generated a monoclonal antibody (mAb), PAL-1, that inhibits hamster AM binding of unopsonized particles (TiO<sub>2</sub>, Fe<sub>2</sub>O<sub>3</sub>, and latex beads; 66 ± 5, 77 ± 2, and 85 ± 2% inhibition, respectively, measured by flow cytometry). This antibody identifies a protein of ~70 kD on the AM surface (immunoprecipitation) that is expressed by AMs and other macrophages in situ. A cDNA clone encoding the mAb PAL-1-reactive protein isolated by means of COS cell expression was found to be 84 and 77% homologous to mouse and human scavenger receptor MARCO mRNA, respectively. Transfection of COS cells with MARCO cDNA conferred mAb-inhibitable TiO<sub>2</sub> binding. Hamster MARCO also mediates AM binding of unopsonized bacteria (67 ± 5 and 47 ± 4% inhibition of *Escherichia coli* and *Staphylococcus aureus* binding by mAb PAL-1). A polyclonal antibody to human MARCO identified the expected ~70-kD band on Western blots of lysates of normal bronchoalveolar lavage (BAL) cells (>90% AMs) and showed strong immunolabeling of human AMs in BAL cytocentrifuge preparations and within lung tissue specimens. In normal mouse AMs, the anti-MARCO mAb ED31 also showed immunoreactivity and inhibited binding of unopsonized particles (e.g., TiO<sub>2</sub> ~40%) and bacteria. The novel function of binding unopsonized environmental dusts and pathogens suggests an important role for MARCO in the lungs' response to inhaled particles.

Key words: MARCO • alveolar • macrophage • unopsonized • environmental particle

Normal breathing inevitably results in deep penetration into the lungs of various environmental particles and microorganisms. The alveolar macrophage (AM)<sup>1</sup> is the cell that is primarily responsible for the binding, ingestion, and, ultimately, clearance of inhaled particulate matter (1, 2). If inhaled microorganisms are opsonized by antibodies and/or complement, AMs can bind and phagocytose them via Fc and C receptors (3, 4). AMs more frequently encounter var-

ious unopsonized environmental particles that they nevertheless bind and ingest with remarkable avidity (5, 6). The AM response to inhaled particles ranges from abundant production of inflammatory cytokines and reactive oxygen intermediates to simple ingestion and clearance with minimal inflammation (7–9). The latter capacity is especially useful for clearance of inert dusts and particles without risk of the potentially damaging effects of an unnecessary inflammatory response. Thus, receptor-mediated binding of inhaled particles and modulation of AM activation are important first steps in the maintenance of lung homeostasis.

Previous work in our laboratory identified a role for scavenger-type receptor(s) in this process (10). The scaven-

<sup>1</sup>Abbreviations used in this paper: AM, alveolar macrophage; BAL, bronchoalveolar lavage; BSS, balanced salt solution; CS, chondroitin sulfate; PI, polyinosinic acid; RAS, right angle scatter; SR, scavenger receptor; SRCR, scavenger receptor cysteine-rich domain.

ger receptors (SRs) are characterized by high-affinity binding of a relatively broad array of ligands such as modified LDL, some (but not all) polynucleotides and polysaccharides, and bacterial endotoxin (11, 12). There are three classes of SRs, A, B, and C (13). The two class A SRs, type I and type II, are homotrimeric glycoproteins composed of three 77-kD monomers generated from alternative splicing of a message encoded by a single gene (14, 15). SR-As are abundant on monocytes and tissue macrophages as well as other cells (13, 16, 17). A recently identified SR-A, MARCO, also binds acetylated LDL (18, 19). MARCO, like SR-A, binds bacteria but not yeast and is expressed on peritoneal macrophages and splenic marginal zone macrophages but has not been found in the lung (18–21).

The SR ligand polyinosinic acid (PI) caused a marked inhibition of AM binding of oxide particles, latex beads, fly ash, and particles collected from ambient air (10, 22). PI also inhibited the uptake of quartz particles ( $\text{SiO}_2$ ) by AMs in vivo (10). These data suggested that SR-like receptors mediate nonopsonic phagocytosis of pollutant particles. Although SR-A (I/II) seemed the most likely candidate, the use of PI precluded precise identification of receptor(s), as this reagent can inhibit more than one member of the SR family (11, 13).

In the studies reported here, we found that SR-A-deficient AMs exhibited normal (comparable to wild-type) ability to bind particles both in vitro and in vivo. To identify other scavenger-type receptors involved, we developed an mAb capable of blocking hamster AM particle binding. Using this mAb, we performed expression cloning for the receptor, which is similar to mouse and human MARCO in cDNA sequence homology and binding of bacteria. We also show that mouse and human AMs express MARCO and that mouse MARCO is involved in binding of unopsonized particles. The results indicate that MARCO is likely to play an important role in the initial responses to inhaled particles in the lung.

## Materials and Methods

**Reagents and Particles.**  $\text{TiO}_2$  and  $\text{Fe}_2\text{O}_3$  were provided by Dr. J. Brain (Harvard School of Public Health, Boston, MA). These particles have been shown to be heterogeneous in size, with a median diameter of 1.3  $\mu\text{m}$  (23). Latex beads (1.0  $\mu\text{m}$  in diameter; sulfated polystyrene) that show green fluorescence after excitation at 488 nm were obtained from Interfacial Dynamics Co. All particles were suspended in balanced salt solution (BSS<sup>-</sup> [124 mM NaCl, 5.8 mM KCl, 10 mM dextrose, and 20 mM Hepes]) as stock solutions and sonicated  $\sim 30$  s before use. Anti-TNP (PharMingen), anti-heparan sulfate mAbs (Seikagaku Corp.), anti-human  $\beta 2$  microglobulin mAb (PharMingen), and a nonspecific rat IgG1 (PharMingen) were used as isotype-matched controls. The anti-human MARCO antibody was raised in rabbits as described (18). The anti-mouse MARCO mAb, ED31 (IgG1), was provided by Dr. G. Kraal (Vrije Universiteit, Amsterdam, The Netherlands) (21). All reagents not otherwise specified were obtained from Sigma Chemical Co.

**Cell Isolation and Flow Cytometric Assay of Particulate Binding.** SR-A-deficient mice were prepared as reported (24). Mice or hamsters were killed by intraperitoneal pentobarbital injection.

AMs obtained by repeated lung lavage with BSS<sup>-</sup> were centrifuged at 150  $g$  and resuspended in BSS<sup>+</sup>. AMs ( $2 \times 10^5$  in 100  $\mu\text{l}$  BSS<sup>+</sup>) were preincubated with mAbs (100  $\mu\text{l}$  hybridoma supernatant or 10  $\mu\text{g}/\text{ml}$  mAb) or inhibitors (10  $\mu\text{g}/\text{ml}$ ) and 2.5  $\mu\text{g}/\text{ml}$  cytochalasin D for 5 min on ice in a 1-ml microfuge tube. After the addition of probe sonicated particles or beads, the tubes were rotated at 37°C for 30 min, placed on ice, and analyzed by flow cytometry. Flow cytometry was performed using an Ortho 2150 cytofluorograph as previously described (25). AM uptake of particles was measured using the increase in the mean right angle scatter (RAS) caused by these granular materials (25). Latex bead binding is expressed as relative fluorescence.

**Assay of Bacteria Binding.** Fluorescent-labeled, heat-killed bacteria (*Escherichia coli* and *Staphylococcus aureus*) and yeast (Zymosan) were purchased from PharMingen. The bacteria binding assay was performed exactly as described above, except that AMs were incubated with either bacteria ( $5 \times 10^7$ ) or yeast ( $2 \times 10^5$ ) instead of particles. Binding was measured by detecting AM-associated fluorescence by flow cytometry.

**In Vivo Particle Uptake.** Mice were anaesthetized with halothane (4%), and 125  $\mu\text{l}$   $\text{TiO}_2$  (50  $\mu\text{g}/\text{ml}$ ) in BSS<sup>+</sup> was instilled into the lungs using a 22-gauge canula. Bronchoalveolar lavage (BAL) was performed 30 min after instillation, and aliquots of BAL were immediately analyzed by flow cytometry to quantify cell-associated particles.

**Production of mAb.** BALB/c mice were immunized by intraperitoneal injection of  $2 \times 10^7$  hamster AMs. After 3 wk, mice received another injection of  $2 \times 10^7$  AMs i.p., and 3 d later, spleens of the mice were removed. The splenocytes were fused with a nonsecreting mouse myeloma, P3U1, using polyethylene glycol 4000 and cultured in DMEM containing hypoxanthine, aminopterin, and thymidine. After 2 wk, supernatants from hybridoma cultures were screened for their ability to inhibit the adhesion of  $\text{TiO}_2$  to AMs.

**Immunoprecipitation.** Hamster AM cell surface proteins were labeled with sulfo-NHS-LC-biotin (Pierce Chemical Co.) as per the manufacturer's suggested protocol and resuspended at a concentration of  $4 \times 10^7$  cells/ml in a 1% extraction buffer (1% Triton X-100, 50 mM Tris-HCl, 150 mM NaCl, 2 mM  $\text{CaCl}_2$ , 2 mM  $\text{MgCl}_2$ , and 5 mM iodoacetamide supplemented with 40  $\mu\text{g}/\text{ml}$  PMSF, 2  $\mu\text{g}/\text{ml}$  aprotinin, and 10  $\mu\text{g}/\text{ml}$  phenanthroline as protease inhibitors). The lysates were precleared with rat anti-mouse IgM magnetic beads (Dynabeads<sup>®</sup>; Dynal Inc.). Aliquots of lysate were incubated with mAbs PAL-1 or RP-3 bound to rat anti-mouse IgM magnetic beads overnight at 4°C. The immunoprecipitates were washed in cold lysis buffer (without protease inhibitors), subjected to SDS-PAGE, electroblotted to membrane filters, probed with avidin-HRP conjugate (Pierce Chemical Co.), and developed using chemiluminescence reagent (Supersignal<sup>®</sup>; Pierce Chemical Co.).

**Immunohistochemistry.** Cryostat sections of hamster tissues were fixed in buffered 2% paraformaldehyde for 10 min, followed by 10 min in 100% cold ( $-20^\circ\text{C}$ ) methanol. After rinsing, immunostaining was performed by sequential application of primary antibody (mAb PAL-1 [5  $\mu\text{g}/\text{ml}$ ] or anti-heparan sulfate mAb [5  $\mu\text{g}/\text{ml}$ ], goat anti-mouse IgG [1:50; Sternberger Monoclonals, Inc.], and mouse peroxidase-antiperoxidase complex [1:100; Sternberger Monoclonals, Inc.]), followed by labeling with chromogen diaminobenzidine and  $\text{H}_2\text{O}_2$ . To increase sensitivity, an additional cycle of secondary and peroxidase-antiperoxidase complex was applied to sections, followed by a second chromogen reaction. Paraffin sections of human lung tissue were immunostained using an avidin-biotin complex protocol as previously described (26). The slides were washed with water, counterstained with hematoxylin, dehydrated, and mounted for light microscopy.

**Expression Cloning.** A hamster AM cDNA library prepared in the pcDM8 vector (provided by Dr. B. Seed, Harvard Medical School, Boston, MA; Paulauskis, J., unpublished data) was divided into small pools and transfected into COS cells. The transiently transfected COS cells were isolated by "panning" on mAb PAL-1-coated plates, and plasmid DNA was reisolated and amplified as described (27). A receptor-positive pool was identified by PAL-1 immunostaining of transfected COS cells after six rounds of screening. This pool was subdivided repeatedly until we obtained a single functional plasmid that upon transfection conferred mAb PAL-1 reactivity to COS cells. Both strands of the cDNA insert were sequenced at the Harvard University Biopolymers Laboratory.


**Western Blot Analysis.** Human AMs were collected by BAL from healthy adults under an institutionally reviewed and approved protocol. AMs were washed and lysates prepared as described above (see *Immunoprecipitation*). The lysates were mixed with 6× reducing or nonreducing SDS-solubilization buffer, subjected to SDS-PAGE, electroblotted to membrane filters, probed with either control rabbit IgG or purified rabbit anti-human MARCO antibody followed by avidin-HRP conjugate (Pierce Chemical Co.), and developed using chemiluminescence reagent (Supersignal®; Pierce Chemical Co).

**Statistics.** Data were analyzed using ANOVA and paired *t* test components of a statistical software package (Statview; Abacus Concepts). Significance was accepted when  $P < 0.05$ .

## Results

**SR-A-deficient AMs Bind Unopsonized Particles.** To determine whether SR-A (I/II) receptors mediate AM binding of unopsonized particles, the binding of  $\text{TiO}_2$  by SR-A (I/II)-deficient AMs ( $\text{SR-A}^{-/-}$ ) was tested and compared with the binding of  $\text{TiO}_2$  by AMs from wild-type mice ( $\text{SR-A}^{+/+}$ ). Microscopic evaluation of treated AMs showed similar robust binding of  $\text{TiO}_2$  by both  $\text{SR-A}^{-/-}$  and  $\text{SR-A}^{+/+}$  AMs (Fig. 1 A). Quantitation by flow cytometric analysis of RAS increases showed that  $\text{SR-A}^{-/-}$  and  $\text{SR-A}^{+/+}$  AMs demonstrated essentially identical particle binding (Fig. 1 B).  $\text{SR-A}^{-/-}$  AMs also bound unopsonized ferric oxide and fluorescent latex beads with comparable avidity (data not shown). The SR ligand PI inhibited the adhesion of  $\text{TiO}_2$  to both  $\text{SR-A}^{-/-}$  and  $\text{SR}^{+/+}$  AMs by  $59 \pm 1\%$  and  $58 \pm 4\%$ , respectively. The control polyanion, chondroitin sulfate (CS), had no effect on particle adhesion. To determine if the *in vitro* particle binding reflected *in vivo* events, we measured particle binding to AMs after intratracheal instillation of  $\text{TiO}_2$ .  $\text{SR-A}$ -deficient or wild-type mice were instilled with buffer alone or buffer containing  $\text{TiO}_2$ . After 30 min, mice were killed, BAL performed, and AM uptake of  $\text{TiO}_2$  quantified by flow cytometry. As shown in Fig. 1 C, both  $\text{SR-A}$ -deficient AMs and wild-type AMs bound  $\text{TiO}_2$  *in vivo* to a comparable degree. Thus,  $\text{SR-A}$  deficiency does not alter unopsonized particle binding by AMs. These results suggested that SRs other than  $\text{SR-A}$  are involved in unopsonized particle binding to AMs.


**Effect of mAb PAL-1 on AM Binding of Particles.** To develop an mAb to the receptor that mediates particle binding, mice were immunized with hamster AMs, and hybridomas were prepared and screened for mAbs that block AM



**Figure 1.**  $\text{SR-A}$ -deficient and -sufficient AMs bind  $\text{TiO}_2$  equally. (A) Representative photomicrograph showing approximately similar binding of particles by  $\text{SR-A}$ -deficient ( $\text{SR}^{-/-}$ ) and wild-type ( $\text{SR}^{+/+}$ ) AMs incubated with unopsonized  $\text{TiO}_2$  (original magnification 400). (B)  $\text{SR}^{-/-}$  and  $\text{SR}^{+/+}$  AMs were pretreated with the SR blocker PI or the control polyanion CS or left untreated, and their binding of  $\text{TiO}_2$  was determined by flow cytometry. (C)  $\text{SR}^{-/-}$  and  $\text{SR}^{+/+}$  AMs show similar binding of  $\text{TiO}_2$  *in vivo* as determined by intratracheal instillation of  $\text{TiO}_2$  followed by BAL and flow cytometric analysis.  $\text{TiO}_2$  binding is expressed as increase in flow cytometric RAS. The data represent the mean ( $\pm$  SEM) of three separate experiments (B) and three mice per treated group compared with one control (C). \*Significantly different from  $\text{TiO}_2$  alone,  $P < 0.006$ .

binding of  $\text{TiO}_2$ . As shown in Fig. 2 and reported previously (10), the scavenger receptor ligand, PI, blocked AM binding of  $\text{TiO}_2$  and served as a positive control for these assays. A new mAb, PAL-1, inhibited AM binding of  $\text{TiO}_2$  by  $67 \pm 5\%$  ( $n = 10$ ). An isotype-matched control mAb (anti-TNP) had no effect on AM binding of  $\text{TiO}_2$ . We next examined the effect of mAb PAL-1 on AM binding of other environmental particles such as  $\text{Fe}_2\text{O}_3$  or quartz ( $\text{SiO}_2$ ) and the surrogate particle, latex beads. As shown in Table I, PAL-1 inhibited AM binding of  $\text{Fe}_2\text{O}_3$ ,  $\text{SiO}_2$ , and latex beads by  $78 \pm 2$ ,  $52 \pm 24$ , and  $85 \pm 4\%$ , respectively. Thus, mAb PAL-1 substantially inhibits AM binding of a broad range of particles.

**Immunoprecipitation of a Cell Surface Protein by mAb PAL-1.** To identify the protein(s) recognized by mAb PAL-1, immunoprecipitation experiments were carried out. AMs were surface-labeled by sulfo-NHS-biotin (Pierce Chemical



**Figure 2.** The mAb PAL-1 blocks AM binding of TiO<sub>2</sub>. Hamster AMs were untreated or pretreated with PI, CS, mAb PAL-1, and an isotype-matched control mAb (IgM), and their binding of TiO<sub>2</sub> was determined by flow cytometry as described in Materials and Methods. TiO<sub>2</sub> binding is expressed as increase in flow cytometric RAS. The data represent mean (± SEM) of 10 separate experiments. \*Significantly different from TiO<sub>2</sub> alone,  $P < 0.001$ .


Co.), and the cell surface molecules bound by PAL-1 were analyzed by SDS-PAGE (Fig. 3). In both reducing and nonreducing conditions, a single band with an apparent molecular mass of 70 kD was detected in lysates of normal AMs (Fig. 3). This band was absent from cells precipitated with an isotype-matched (IgM) negative control antibody.

**Tissue Localization of the PAL-1 Antigen.** Immunostaining of frozen sections from a range of normal hamster tissues with PAL-1 showed that it reacted strongly with most or all AMs, macrophages of lymph node sinuses, and von Kupffer cells of the liver (Fig. 4 A). Macrophages in other sites were also positive (e.g., splenic red pulp, intestinal Peyer's patch, thymus). Cross-reactions with other tissue structures such as endothelial cells were not observed; numerous other nonlymphoid tissues were negative (skin, brain, heart, stomach, prostate, and kidney; data not shown). Flow cytometric analysis showed that PAL-1 staining is detected on AMs. Lymphocytes isolated from different lymph nodes and thymocytes were negative (Fig. 4 B). Peritoneal

**Table I.** mAb PAL-1 Inhibits AM Binding of a Panel of Unopsonized Particles

Particle	Percent inhibition
TiO <sub>2</sub> ( $n = 10$ )	67 ± 5
Fe <sub>2</sub> O <sub>3</sub> ( $n = 2$ )	78 ± 2
Sulfated latex beads ( $n = 2$ )	85 ± 3
SiO <sub>2</sub> ( $n = 3$ )	52 ± 24

Hamster AMs were left untreated or pretreated with mAb PAL-1 or an isotype-matched control mAb and their binding of particles determined as described in Materials and Methods. Particle binding is expressed as percent inhibition of TiO<sub>2</sub> ( $n = 10$ ), Fe<sub>2</sub>O<sub>3</sub> ( $n = 2$ ), latex bead ( $n = 2$ ), and SiO<sub>2</sub> ( $n = 3$ ) binding by mAb PAL-1. No significant inhibition of particle binding was observed with a control IgM (range is from -18 to 7% inhibition).




**Figure 3.** Immunoprecipitation of the AM surface protein recognized by mAb PAL-1. Hamster AMs were surface-labeled with sulfo-NHS-biotin, extracted with Triton X-100, pre-cleared with anti-mouse IgM magnetic beads, and immunoprecipitated with mAb PAL-1 or a control IgM bound to anti-mouse magnetic beads. Immunoprecipitates were analyzed using reducing (R) or nonreducing (NR) SDS-PAGE as described in Materials and Methods. Relative molecular mass is indicated (kD).

macrophages, neutrophils, and monocytes were predominantly negative (data not shown).


**Expression Cloning of the Particle Adhesion Receptor.** An expression cloning protocol was used to identify the receptor mediating AM binding of particles. When transfected into COS cells, a cDNA clone conferred mAb PAL-1 reactivity (Fig. 5, A and B). Both strands of the 1.6-kb insert were sequenced. The sequence, including part of the 5'- and 3'-untranslated regions, is shown in Fig. 6 A. From the first ATG, we predict an open reading frame of 1452 bp, which yields a protein of 483 amino acid residues with a predicted molecular mass of 49.5 kD. GenBank searches of the nucleotide and protein sequences revealed significant homology to murine and human MARCO (84 and 77% nucleotide identity with mouse and human MARCO cDNA, respectively; 18, 19). We refer to this clone as hamster MARCO. Amino acid identity between hamster, murine, and human MARCO was 77 and 65%, respectively (Fig. 6 B). As shown in Table II, amino acid identity between hamster, mouse, and human MARCO was highest in the collagenous domain. The intracellular domain had 80% identity between hamster and mouse MARCO, as compared with 50% identity between hamster and human MARCO. Hamster MARCO, like human MARCO, does not have a cysteine residue in the spacer domain, but like mouse MARCO, it retains two cysteines in the cytoplasmic domain. The two potential carbohydrate attachment sites in the spacer domain, the interruption of Gly-Xaa-Yaa repeats in the collagenous domain, and all six cysteine residues in the scavenger receptor cysteine-rich domain (SRCR) are conserved between all three species (Fig. 6 B). Hamster MARCO differs from both murine and human MARCO in containing a shorter collagenous domain (237 amino acids).

**MARCO Expression Confers mAb PAL-1-inhibitable TiO<sub>2</sub> Binding to COS Cells.** To confirm the role of MARCO in particle binding, we transfected COS cells with hamster MARCO cDNA. As shown in Fig. 5 C, COS cells transfected with MARCO cDNA bound TiO<sub>2</sub> (4.6-fold increase in RAS). TiO<sub>2</sub> binding by MARCO-transfected

A



B



**Figure 4.** Immunohistochemical detection of the molecule recognized by PAL-1. (A) Photomicrographs of cytopins of hamster BAL cells. Frozen sections of lung, liver, and lymph nodes were stained with mAb PAL-1 or an irrelevant control mAb. Original magnification: 400 for BAL cells, 200 for tissue sections. (B) The expression of the molecule recognized by mAb PAL-1 was analyzed by flow cytometry. Single-cell suspensions prepared from the indicated organs (CLN, cervical lymph node; MLN, mesenteric lymph node; PP, Peyer's patch; PMN, neutrophils) or hamster BAL (AM) were incubated with either mAb PAL-1 or an isotype-matched control mAb followed by goat anti-mouse IgM-FITC and analyzed by flow cytometry. The data are presented as relative fluorescence intensity (mean channel number from flow cytometric analysis). White bar, control; hatched bar, IgM; black bar, PAL-1.

COS cells but not untransfected COS cells was significantly inhibited by the anti-MARCO mAb PAL-1 ( $47 \pm 6\%$  inhibition; Fig. 5 C). Controls, including untransfected COS cells and COS cells transfected with a plasmid encoding the cDNA for hamster CD44, exhibited binding of  $\text{TiO}_2$  that

was inhibited by both PI and heparin (an agent that does not inhibit AM binding of  $\text{TiO}_2$  [10]) but not mAb PAL-1 (data not shown). The constitutive heparin-sensitive particle-binding receptor on COS cells is different from MARCO and remains to be identified (see Discussion).



**Table II.** Amino Acid Identity between Hamster, Mouse, and Human MARCO


Hamster MARCO domains	Percent amino acid identity	
	Human MARCO	Mouse MARCO
Cytoplasmic	48	77
Transmembrane	61	78
Spacer	58	65
Collagenous	76	77
SRCR	65	77
Across all domains	65	77

Amino acid identity was determined by comparing the indicated putative domains with each other using the Align program in the Biology Workbench (<http://biology.ncsa.uiuc.edu>).

**Hamster MARCO Mediates AM Binding of Bacteria.** To further investigate the range of ligands for hamster MARCO, we tested the effect of mAb PAL-1 on AM binding of unopsonized microorganisms. As shown in Fig. 7, mAb PAL-1 inhibited AM binding of *E. coli* and *S. aureus* by  $67 \pm 5\%$  and  $47 \pm 4\%$ , respectively. PAL-1 had no effect on AM binding of Zymosan. An isotype-matched control antibody did not inhibit bacteria and yeast binding. Thus hamster MARCO, like human and mouse MARCO (18, 19), mediates AM binding of bacteria but not yeast.

**Expression of MARCO on Human Cells.** The original report of human MARCO did not detect MARCO expression in the lungs of a limited number of perinatal autopsy specimens (18). To evaluate whether adult human AMs express MARCO, we performed immunologic analysis using a polyclonal antibody to a peptide from domain V of human MARCO (18). Histochemical analysis of human BAL cells (>90% AMs) and lung tissue showed that the anti-MARCO antibody detects antigen on AMs but not on other cells or surrounding tissue structures (Fig. 8, A-D). We prepared lysates from human AMs ( $n = 5$ ) and performed SDS/Western blot analysis. The anti-human MARCO antibody reacted specifically with a discrete band in all AM lysates, which ran at a relative molecular mass of  $\sim 70$  kD (results from two samples are shown in Fig. 8 E). No reactivity was seen with an irrelevant control antibody. The same pattern was repeated when the analysis was performed in nonreducing conditions (data not shown). Thus, adult human AMs express MARCO.

**SR-A-deficient AM Binding of TiO<sub>2</sub> Is Inhibited by an Antibody to MARCO.** An mAb to mouse MARCO has been shown to block bacteria binding by mouse macrophages (19). Although expression of MARCO was not detected in mouse lungs in the original report, we found significant immunostaining (albeit weaker than that seen in human and hamster AMs) of normal mouse AMs by the anti-MARCO mAb ED31 (data not shown; see Discussion) (19). We therefore examined whether ED31 would block TiO<sub>2</sub> binding by mouse AMs. In these experiments, the SR inhibitor, PI, re-




**Figure 7.** Effect of mAb PAL-1 on bacteria and yeast binding by AMs. Hamster AMs were left untreated or pretreated with PI, CS, mAb PAL-1, and a control mAb (IgM). Following pretreatment, AM binding of *E. coli*, *S. aureus*, and the yeast particle *Saccharomyces cerevisiae* (Zymosan) was determined by flow cytometry. The data represent mean ( $\pm$  SEM) green fluorescence of four separate experiments. \*Significantly different from particle alone,  $P < 0.05$ .

duced TiO<sub>2</sub> binding by  $44 \pm 12$  and  $52 \pm 11\%$  in SR<sup>-/-</sup> and SR<sup>+/+</sup> mice, respectively; the control polyanion CS had no significant effect ( $n \geq 3$ ). Treatment of SR<sup>-/-</sup> AMs with ED31 blocked binding of TiO<sub>2</sub> by  $40 \pm 11\%$  ( $n = 4$ ). TiO<sub>2</sub> binding by SR<sup>+/+</sup> was also inhibited by anti-MARCO mAb treatment by  $25 \pm 4\%$  ( $n = 3$ ). Control IgG1 had no effect on binding. Similar inhibition of mouse AM binding of unopsonized fluorescent latex beads and bacteria was seen (data not shown). Thus, MARCO also functions to bind environmental particles and bacteria in mouse AMs.

## Discussion

In this study, we have identified MARCO as a major receptor on AMs for binding of unopsonized environmental particles and certain microorganisms. The lung is constantly exposed to environmental substances such as microbes, pollutant particles, and allergens. The levels of ambient air particles in the environment have been correlated with increased morbidity and mortality (28-31). The clearance of inhaled particulate matter is primarily mediated by AMs through the process of phagocytosis (1, 2). AMs have been previously shown to avidly phagocytose unopsonized particles (5, 6). However, the receptors on the AMs that recognize and bind particles are not known. Here we have gen-



**Figure 8.** (A–D) Human AMs express MARCO. Immunostaining of normal volunteer BAL cytocentrifuge preparations (A) and surgical lung tissue specimens (C) showed strong labeling by a rabbit anti-human MARCO antibody; control rabbit IgG showed only minimal nonspecific background staining (B, D) (original magnification 400). (E) Lysates prepared from BAL cells collected from adult volunteers (2/5 similar results shown) were analyzed by reducing SDS-PAGE and immunoblotted with a rabbit anti-human MARCO antibody or control rabbit IgG (Ctrl). Relative molecular mass standards are indicated (kD).

erated an mAb, PAL-1, that blocked particle and bacteria binding by AMs. Using mAb PAL-1 as a probe, we have cloned the cDNA encoding for the receptor from an AM cDNA library. Transfection of COS cells conferred mAb PAL-1 reactivity and mAb PAL-1-inhibitable binding of  $\text{TiO}_2$ . By sequence homology and functional similarity, we conclude that the receptor is the hamster homologue of MARCO.

The recognition of phagocytic targets is mediated by specific receptors on the phagocytes that either recognize serum components (opsonins) bound to the particle or directly recognize molecular determinants on the target. Thus, based on the mechanism of particle recognition, phagocytosis is either opsonin-dependent or opsonin-independent. The best characterized opsonin-dependent phagocytosis receptors are the  $\text{Fc}\gamma$  receptor and the complement receptor CR3 (3, 32). Recent advances have highlighted the significance of other receptors, such as the collectin receptor, C1q, in opsonin-dependent phagocytosis (33, 34). The opsonin-independent recognition of microorganisms and apoptotic cells is mediated by receptors such as the scavenger receptor, mannose receptor, vitronectin receptor, asialoglycoprotein receptor, and the  $\beta 2$  integrins (35–37). Based on the high expression of SRs on macrophages and their broad specificity, we considered this class of receptors as likely suspects for interaction with inhaled particles. Indeed, we found that AM phagocytosis of unopsonized environmental dusts ( $\text{TiO}_2$ ,  $\text{Fe}_2\text{O}_3$ ,  $\text{SiO}_2$ ) or fluorescent latex beads is strongly inhibited by the SR blocker, PI (10). To more precisely determine the role of SR-A in

this interaction, we examined the ability of AMs from SR-A (I/II)-deficient mice (24) to bind particles. We showed that both wild-type and SR-A-deficient macrophages bound unopsonized  $\text{TiO}_2$  (Fig. 1),  $\text{Fe}_2\text{O}_3$ , and latex beads essentially identically (data not shown). The scavenger receptor ligand PI inhibited the binding of particles to SR-A-deficient macrophages, suggesting that AMs express additional SR-like molecules that mediate opsonin-independent phagocytosis of particulate matter. To identify this receptor, we generated a monoclonal antibody, PAL-1, which blocked AM binding of particles (Fig. 2 and Table I). Using this antibody, we have cloned the cDNA encoding this receptor. Transfection of COS cells with this cDNA clone confers mAb PAL-1 reactivity (Fig. 5 A). Importantly, transfection confers PAL-1-inhibitable binding of  $\text{TiO}_2$  by COS cells (Fig. 5 C).

Interpretation of the COS cell transfection experiments was complicated by the observation that COS cells constitutively bind particles to a substantial degree. This indicated the presence of endogenous particle adhesion receptor(s). However, transfection of COS cells with MARCO but not control plasmid or cDNA resulted in mAb PAL-1-inhibitable particle binding (Fig. 5 C). Importantly, the constitutive COS cell receptor(s) for particles is sensitive to heparin inhibition, whereas AM receptor-mediated particle binding is not heparin sensitive (10). Interestingly, transfection with MARCO, in addition to conferring mAb PAL-1-inhibitable particle binding, substantially diminished the component that was heparin inhibitable (data not shown). We speculate that the transfected cDNA competes with the endoge-

nous COS cell particle receptor(s) for either surface expression or binding function. Existence of a particle-binding receptor on nonphagocytes such as COS cells is not unprecedented. The lung epithelial cell line A549 binds and ingests unopsonized TiO<sub>2</sub>, and this binding can also be inhibited by PI and heparin (38).

The particle-binding receptor on hamster AMs is similar to murine and human MARCO (Fig. 6). Murine MARCO was originally identified by screening a murine macrophage cDNA library with a human type XIII collagen probe. Murine MARCO is a 210-kD trimer made up of three disulfide-linked, 52-kD monomers and is expressed only on macrophages in spleen and lymph nodes (19). Human MARCO was recently cloned by screening human liver and spleen cDNA libraries with a murine MARCO probe (18). Human MARCO shares 68% sequence identity with mouse MARCO. Hamster MARCO had higher sequence identity to mouse than to human MARCO across all domains (Table II). Interestingly, hamster MARCO has a shorter collagenous domain (less 34 amino acids) than both human and mouse MARCO. Also, like human MARCO, hamster MARCO does not have a cysteine residue in the spacer domain. The six cysteines in the cysteine-rich domain are conserved in all three species (Fig. 6). The cysteine-rich domain defines a recently identified family of proteins (39). The true function of the SRCR is not clear. Hamster MARCO, like mouse and human MARCO, binds bacteria but not yeast (Fig. 7; references 19, 21).

The expression of MARCO on normal AMs merits discussion. Initially, both human and mouse MARCO were not detected in normal lung (18, 19). Using Western blot and immunolabeling techniques, we detected MARCO expression in normal lavaged AMs and AMs presented in

diseased lungs (surgical specimens) (Fig. 8). The use of adult AMs may explain the difference between this finding and the absence of mRNA in neonatal lungs (18). In mouse AMs, we have detected faint but reproducible immunoperoxidase labeling, using mAb ED31, of normal BAL AMs. This antibody also partially blocks mouse AM binding of particles, indicating that low levels of ED31 (MARCO) are present and functional on these cells. In these studies, we used normal, healthy looking mice housed in conventional facilities, not a "clean room" barrier facility. Expression of MARCO is induced on lung and liver macrophages in mice infected with *Klebsiella pneumoniae* (21). It is possible that our mice expressed MARCO because of low-level activation from their less clean environmental surroundings, a possibility yet to be formally tested. It is also noteworthy that both PI and anti-MARCO (ED31) cause lower levels of inhibition of unopsonized particle binding by mouse AMs compared with that seen with hamster AMs. Whether this reflects a significant difference (e.g., the presence of other receptor[s]), minor species, or technical variables remains to be determined.

Our finding that MARCO mediates AM binding of particles defines a novel and immunologically important function for MARCO. As MARCO mediates binding of both inert particles and potentially pathogenic microorganisms, it will be interesting to determine how binding by MARCO modulates AM bactericidal functions. Specifically, the laudable absence of AM activation that accompanies binding (and ingestion) of inert environmental dusts may prove harmful for encounters with viable pathogens. Additional studies of the function of MARCO may provide more insight into the role of AMs in the initial, innate response of the lung to inhaled particles and pathogens.

---

We thank Dr. Scott Shepard and Marshall Katler for assistance in sequencing and Dr. G. Kraal for providing anti-mouse MARCO antibodies.

This work was supported by grants NIEHS 00002 and ES08129.

This study complies with National Institutes of Health guidelines and was approved by the Institutional Review Committees on Animals of the Harvard School of Public Health.

Address correspondence to Lester Kobzik, Physiology Program, Harvard School of Public Health, 665 Huntington Ave., Boston, MA 02115. Phone: 617-432-2247; Fax: 617-432-0014; E-mail: lkobzik@hsph.harvard.edu

*Received for publication 17 February 1999.*

## References

1. Brain, J.D. 1985. Macrophages in the respiratory tract. *In* Handbook of Physiology. I.A.P. Fishman, editor. American Physiological Society, Bethesda, MD. 447-471.
2. Bowden, D. 1987. Macrophages, dusts and pulmonary diseases. *Exp. Lung Res.* 12:89-99.
3. Swanson, J.A., and S.C. Baer. 1998. Phagocytosis by zippers and triggers. *Trends Cell Biol.* 5:89-93.
4. Brown, E.J. 1994. Phagocytosis. *Bioessays.* 17:109-117.
5. Parod, R., and J.D. Brain. 1983. Uptake of latex particles by macrophages: characterization using flow cytometry. *Am. J. Physiol.* 245:C220-C225.
6. Parod, R.J., and J.D. Brain. 1986. Immune opsonin-independent phagocytosis by pulmonary macrophages. *J. Immunol.* 136:2041-2049.
7. Kobzik, L., J.D. Godleski, and J.D. Brain. 1990. Selective down-regulation of alveolar macrophage oxidative response

- to opsonin-independent phagocytosis. *J. Immunol.* 144:4312–4319.
8. Becker, S., R.B. Devlin, and J.S. Haskill. 1989. Differential production of tumor necrosis factor, macrophage colony stimulating factor, and interleukin 1 by human alveolar macrophages. *J. Leukoc. Biol.* 45:353–361.
  9. Zhang, Y., T.C. Lee, M. Guillemin, C. Yu, and W.N. Rom. 1993. Enhanced IL-1 $\beta$  and tumor necrosis factor- $\alpha$  release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. *J. Immunol.* 150:4188–4196.
  10. Kobzik, L. 1995. Lung macrophage uptake of unopsonized environmental particulates. Role of scavenger-type receptors. *J. Immunol.* 155:367–376.
  11. Krieger, M. 1992. Molecular flypaper and atherosclerosis: structure of the macrophage scavenger receptor. *Trends Biochem. Sci.* 17:141–146.
  12. Hampton, R.Y., D.T. Golenbock, M. Penman, M. Krieger, and C.R. Raetz. 1991. Recognition and plasma clearance of endotoxin by scavenger receptors. *Nature.* 353:342–344.
  13. Krieger, M., and J. Herz. 1994. Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptor and LDL receptor-related protein (LRP). *Annu. Rev. Biochem.* 63:601–637.
  14. Kodama, T., M. Freeman, L. Rohrer, J. Zabrecky, P. Mutsaers, and M. Krieger. 1990. Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. *Nature.* 343:531–535.
  15. Rohrer, L., M. Freeman, T. Kodama, M. Penman, and M. Krieger. 1990. Coiled-coil fibrous domains mediate ligand binding by macrophage scavenger receptor type II. *Nature.* 343:570–572.
  16. Pearson, A.M. 1996. Scavenger receptors in innate immunity. *Curr. Opin. Immunol.* 8:20–28.
  17. Yamada, Y., T. Doi, T. Hamakubo, and T. Kodama. 1998. Scavenger receptor family proteins: roles for atherosclerosis, host defence and disorders of the central nervous system. *Cell. Mol. Life Sci.* 54:628–640.
  18. Elomaa, O., M. Sankala, T. Pikkarainen, U. Bergmann, A. Tuuhyila, A. Raatikainen-Asokas, H. Sariola, and K. Tryggvason. 1998. Structure of the human macrophage MARCO receptor and characterization of its bacteria-binding region. *J. Biol. Chem.* 273:4530–4538.
  19. Elomaa, O., M. Kangas, C. Sahlberg, J. Tuukanen, R. Sorunen, A. Liakka, I. Thesleff, G. Kraal, and K. Tryggvason. 1995. Cloning of a novel bacteria binding receptor structurally related to scavenger receptors and expressed in a subset of macrophages. *Cell.* 80:603–609.
  20. van der Laan, L.J., E.A. Dopp, R. Haworth, T. Pikkarainen, M. Kangas, O. Elomaa, C.D. Dijkstra, S. Gordon, K.K. Tryggvason, and G. Kraal. 1999. Regulation and functional involvement of macrophage scavenger receptor MARCO in clearance of bacteria in vivo. *J. Immunol.* 162:939–947.
  21. van der Laan, L.J., M. Kangas, E.A. Dopp, E. Broug-Holub, O. Elomaa, K. Tryggvason, and G. Kraal. 1997. Macrophage scavenger receptor MARCO: in vitro and in vivo regulation and involvement in the anti-bacterial host defense. *Immunol. Lett.* 57:203–208.
  22. Goldsmith, C.A., C. Frevert, A. Imrich, C. Sioutas, and L. Kobzik. 1997. Alveolar macrophage interaction with air pollution particulates. *Environ. Health Perspect.* 105:1191–1195.
  23. Beck, B., J.D. Brain, and D. Bohannon. 1982. An in vivo hamster bioassay to assess the toxicity of particulates for the lung. *Toxicol. Appl. Pharmacol.* 66:9–29.
  24. Suzuki, H., Y. Kurihara, M. Takeya, N. Kamada, M. Kataoka, K. Jishaga, O. Ueda, H. Sakaguchi, T. Higashi, T. Suzuki, et al. 1997. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. *Nature.* 386:292–296.
  25. Stringer, B., A. Imrich, and L. Kobzik. 1995. Lung macrophage uptake of environmental particulates: a flow cytometric assay. *Cytometry.* 20:23–29.
  26. Kobzik, L., and H.W. Schmidt. 1996. Immunohistochemistry of nitric oxide synthase and nitric oxide-related products. *In Methods in Nitric Oxide Research.* M. Feelisch and J.S. Stamler, editors. John Wiley and Sons Ltd., New York. 229–236.
  27. Coligan, J.E., A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, and E.M. Strober, editors. 1994. Use of monoclonal antibodies for expression cloning. *Current Protocols in Immunology.* Vol. 2. John Wiley and Sons, Inc., New York. 10.18.1–10.18.6.
  28. Dockery, D.W., and C.A. Pope III. 1994. Acute respiratory effects of particulate air pollution. *Annu. Rev. Public Health.* 15:107–132.
  29. Schwartz, J., and D.W. Dockery. 1992. Increased mortality in Philadelphia associated with daily air pollution concentrations. *Am. Rev. Respir. Dis.* 145:600–604.
  30. Schwartz, J. 1994. Air pollution and daily mortality: a review and meta analysis. *Environ. Res.* 64:36–52.
  31. Bates, D.V., and R. Sizto. 1983. Relationships between air pollution levels and hospital admissions in Southern Ontario. *Can. J. Public Health.* 74:117–122.
  32. Brown, E.J. 1992. Complement receptors and phagocytosis. *Curr. Opin. Immunol.* 3:76–82.
  33. Holmskov, U., R. Malhotra, R.B. Sim, and J.C. Jensenius. 1994. Collectins: collagenous C-type lectins of the innate immune defense system. *Immunol. Today.* 15:67–74.
  34. Sastry, K., and R.A.B. Ezekowitz. 1993. Collectins: pattern recognition molecules involved in first line host defense. *Curr. Opin. Immunol.* 5:59–66.
  35. Ofek, I., J. Goldhar, Y. Keisari, and N. Sharon. 1995. Non-opsonic phagocytosis of microorganisms. *Annu. Rev. Microbiol.* 49:239–276.
  36. Hart, S.P., C. Haslett, and I. Dransfield. 1996. Recognition of apoptotic cells by phagocytes. *Experientia.* 52:950–956.
  37. Palecanda, A., and L. Kobzik. 1998. Opsonin-independent phagocytosis: role of scavenger type receptors. *Curr. Trends Immunol.* 1:141–147.
  38. Stringer, B., A. Imrich, and L. Kobzik. 1996. Lung epithelial cell (A549) interaction with unopsonized environmental particulates: quantitation of particle-specific binding and IL-8 production. *Exp. Lung Res.* 22:495–508.
  39. Freeman, M., J. Ashkenas, D.J. Rees, D.M. Kingsley, N.G. Copeland, N.A. Jenkins, and M. Krieger. 1990. An ancient, highly conserved family of cysteine-rich protein domains revealed by cloning type I and type II macrophage scavenger receptors. *Proc. Natl. Acad. Sci. USA.* 87:8810–8814.